Author Archives: Center for Biotechnology

Call for Proposals: Applied Research and Development Program 2023

Posted on by
Reply

The Center for Biotechnology has announced a Call for Proposals for our 2023 Applied Research and Development (ARAD) Program. The ARAD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology.

These areas include research technologies, diagnostics, therapeutics and medical devices. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

2023 Proposal Submission:
The deadline for receipt of applications is May 8, 2023, 5pm (updated). No exceptions will be made. Applications are accepted and considered on a competitive basis and are subject to the availability of funds. Approval from the Research Foundation Sponsored Programs is not required prior to submission, but will be required if the project is selected for funding. All applications require a letter-of-support from a senior executive of the company confirming their corporate residency in New York State and financial commitment to match-fund the project. Further details are found within the forms pages. A single PDF version of the proposal and letter of support should be submitted to Center for Biotechnology at center_for_biotechnology@stonybrook.edu.

ARAD Program Forms:

Call for Applications & Guidelines

Application Form

Budget Forms

Anti-Cancer Agent Developed at SBU Shows Great Promise Against Tumors, Receives $24M Investment

Posted on by

A second-generation taxane conjugate in a nanoemulsion formulation (called NE-DHA-SBT-1214) developed by Stony Brook University Distinguished Professor Iwao Ojima in his chemistry laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) and licensed to Dr. James Egan, has received a $24 million investment to be taken to phase 2a development. Preclinical results have persuaded TVM Capital Life Science to invest in the technology via Recurv Pharma.

The VC fund will invest up to $24 million in Recurv through its project-focused company (PFC) investment objective, an initiative focused on backing first or best-in-class candidates that are clearly differentiated from the competition or add clinical value. Read More on Fierce Pharma and via SBU News.

Call for Applications-Spring 2023 Innovation Bootcamp

Posted on by
Reply

Long Island New York I-Corps Hub – Innovation Bootcamp Spring 2023 Program

This Innovation Bootcamp Program will teach scientists, inventors and first-time entrepreneurs the Lean Launchpad Methodology – Customer Discovery through 20 interviews, Agile Development roadmapping, and the Business Model Canvas – specifically Value Propositions and Customer Segments

Kickoff Session: Tuesday, February 14, 9:00 AM – 4:00 PM (Online)
Mid Session: Friday, February 14, 9:15 AM – 4:00 PM (Online) and
Finale Session: Friday, March 3, 9:15 AM – 3:00 PM (Room 109, R&D Park Research and Support Services)

Applications are being reviewed NOW on a rolling basis until 11:59 PM Friday, Feb 3, 2023. Limited space is available – apply early! https://forms.gle/RM8WRrN3VuGVCMgP8

Teams of 1+ faculty, staff, etc. from any university, national lab, or community teams with an Innovation or Research Idea should be STEAM focused are encouraged to apply. Must be able to attend all 3 scheduled workshops and dedicate time outside of the sessions to do customer discovery interviews
For full details and eligibility requirements, please visit https://tinyurl.com/SBUBootcampSpring23

SBU Student & CFB Fundamentals Program Alum
Wins NIH Pitch Competition

Posted on by

Christopher Ashdown, a Stony Brook University MD/PhD student and alumnus of the CFB’s Fundamentals of the Bioscience Industry Program, has won the Innovator Showcase Pitch Event at the 2022 Proof of Concept Network (POCN) Annual Meeting hosted by National Institutes of Health SEED (Small business Education and Entrepreneurial Development). Chris pitched on behalf of Lahara Bio.

Chris advanced through multiple rounds of pitching and was selected to present at the POCN Innovator Showcase with two other exceptional POCN innovators. Congratulations Chris!

Join us at io360! February 7-10 in Brooklyn NY

Posted on by

The 9th annual Immuno-Oncology 360° Summit, taking place February 7-10, 2023 in Brooklyn, NY, offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO.

Center for Biotechnology constituents receive a 15% Discount on registration with code “CFB15”

Learn more at www.IO360Summit.com